<DOC>
	<DOCNO>NCT03077217</DOCNO>
	<brief_summary>Several study show rifaximin improve cognitive function , drive simulator performance health-related quality life patient minimal hepatic encephalopathy . The aim prospective randomize open control study evaluate efficacy safety rifaximin different dos treatment covert hepatic encephalopathy .</brief_summary>
	<brief_title>Low-dose Rifaximin Treatment Covert Hepatic Encephalopathy</brief_title>
	<detailed_description />
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Hepatic Encephalopathy</mesh_term>
	<mesh_term>Rifaximin</mesh_term>
	<mesh_term>Rifamycins</mesh_term>
	<criteria>1 . Patients agree sign inform consent 2 . Patients aged 1870 years，males females 3 . Patients diagnose occult hepatic encephalopathy PHES Stroop test 1 . Allergy rifamycin/rifamutin/rifampin/rifapentine 2 . Current recent ( &lt; 3 month ) use alcohol ca n't stop drinking study period 3 . Use antibiotic within last 6 week 4 . Use lactulose/lactitol , probiotic , LornithineLaspart，zinc，metronidazole , neomycin , rifaximin within last 6 week 5 . Infection gastrointestinal hemorrhage within last 6 week 6 . Use psychoactive drug within last 6 week 7 . Occurred overt hepatic encephalopathy within last 3 month 8. history portosystemic shunt surgery transjugular intrahepatic portosystemic shunt 9 . Poor vision , color blindness motor defect interfere performance psychometric test 10 . Other noncontrollable neurological psychiatric problem may affect cognitive function Alzheimer 's disease , Parkinson 's disease schizophrenia 11 . Conformed highly suspicious diagnosis liver malignant tumor 12 . Human immunodeficiency virus ( HIV ) infection 13 . Uncontrolled hypertension , diabetes serious cardiac pulmonary disease 14 . White blood cell count &lt; 1×10^9/L 15 . Pregnancy breastfeed 16 . Participated drug clinical trial within 3 month 17 . The researcher think suitable clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>covert hepatic encephalopathy</keyword>
	<keyword>low-dose rifaximin</keyword>
</DOC>